DARA BioSciences, Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “DARA BioSciences, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “DARA BioSciences, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- DARA BioSciences, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of DARA BioSciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of DARA BioSciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the DARA BioSciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate DARA BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of DARA BioSciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the DARA BioSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with DARA BioSciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of DARA BioSciences, Inc. and identify potential opportunities in those areas.
DARA BioSciences, Inc. Snapshot
DARA BioSciences, Inc. Overview
Key Information
Key Facts
DARA BioSciences, Inc. – Research and Development Overview
Key Therapeutic Areas
DARA BioSciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
DARA BioSciences, Inc. – Pipeline Products Glance
DARA BioSciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
DARA BioSciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
DARA BioSciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
DARA BioSciences, Inc. – Drug Profiles
Docetaxel
Product Description
Mechanism of Action
R&D Progress
Talabostat + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Talabostat + Pemetrexed Disodium
Product Description
Mechanism of Action
R&D Progress
KRN5500
Product Description
Mechanism of Action
R&D Progress
Talabostat + Rituximab
Product Description
Mechanism of Action
R&D Progress
DB959
Product Description
Mechanism of Action
R&D Progress
DB160
Product Description
Mechanism of Action
R&D Progress
DB200
Product Description
Mechanism of Action
R&D Progress
PT-630
Product Description
Mechanism of Action
R&D Progress
DB900
Product Description
Mechanism of Action
R&D Progress
DARA BioSciences, Inc. – Pipeline Analysis
DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class
DARA BioSciences, Inc. Pipeline Products By Target
DARA BioSciences, Inc. – Pipeline Products by Molecule Type
DARA BioSciences, Inc. – Recent Pipeline Updates
DARA BioSciences, Inc. - Dormant Projects
DARA BioSciences, Inc. – Company Statement
DARA BioSciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 04, 2010: DARA BioSciences Successfully Completes Phase I Clinical Study Of DB959 for Treatment Of Type 2 Diabetes
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer
Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with Novel Therapeutics" Meeting
Nov 19, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The Mechanisms And Treatment Of Neuropathic Pain" Meeting
Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes .
Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions
Mar 10, 2009: United States Food And Drug Administration Approves DARA Investigational New Drug Application (IND) For DB959.
Financial Deals Landscape
DARA BioSciences, Inc., Deals Volume Summary, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary By Region, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
DARA BioSciences, Inc. Detailed Deal Summary
Acquisition
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
Equity Offering
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
Licensing Agreements
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Massachusetts General Hospital
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 74
LIST OF TABLES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, 2010
DARA BioSciences, Inc. – Pipeline by Stage of Development, 2010
DARA BioSciences, Inc. – Monotherapy Products in Pipeline, 2010
DARA BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2010
DARA BioSciences, Inc. – Phase III, 2010
DARA BioSciences, Inc. - Phase II, 2010
DARA BioSciences, Inc. - Phase I, 2010
DARA BioSciences, Inc. - Pipeline By Therapeutic Class, 2010
DARA BioSciences, Inc. - Pipeline By Target, 2010
DARA BioSciences, Inc. – Pipeline By Molecule Type, 2010
DARA BioSciences, Inc. – Recent Pipeline Updates, 2010
DARA BioSciences, Inc. - Dormant Developmental Projects, 2010
DARA BioSciences, Inc., Subsidiaries
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary by Region, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Massachusetts General Hospital 73
LIST OF FIGURES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, 2010
DARA BioSciences, Inc. – Pipeline by Stage of Development, 2010
DARA BioSciences, Inc. – Monotherapy Products in Pipeline, 2010
DARA BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2010
DARA BioSciences, Inc. – Pipeline By Therapeutic Class, 2010
DARA BioSciences, Inc. - Pipeline By Target, 2010
DARA BioSciences, Inc. – Pipeline By Molecule Type, 2010 33
DARA BioSciences, Inc. Overview
Key Information
Key Facts
DARA BioSciences, Inc. – Research and Development Overview
Key Therapeutic Areas
DARA BioSciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
DARA BioSciences, Inc. – Pipeline Products Glance
DARA BioSciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
DARA BioSciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
DARA BioSciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
DARA BioSciences, Inc. – Drug Profiles
Docetaxel
Product Description
Mechanism of Action
R&D Progress
Talabostat + Docetaxel
Product Description
Mechanism of Action
R&D Progress
Talabostat + Pemetrexed Disodium
Product Description
Mechanism of Action
R&D Progress
KRN5500
Product Description
Mechanism of Action
R&D Progress
Talabostat + Rituximab
Product Description
Mechanism of Action
R&D Progress
DB959
Product Description
Mechanism of Action
R&D Progress
DB160
Product Description
Mechanism of Action
R&D Progress
DB200
Product Description
Mechanism of Action
R&D Progress
PT-630
Product Description
Mechanism of Action
R&D Progress
DB900
Product Description
Mechanism of Action
R&D Progress
DARA BioSciences, Inc. – Pipeline Analysis
DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class
DARA BioSciences, Inc. Pipeline Products By Target
DARA BioSciences, Inc. – Pipeline Products by Molecule Type
DARA BioSciences, Inc. – Recent Pipeline Updates
DARA BioSciences, Inc. - Dormant Projects
DARA BioSciences, Inc. – Company Statement
DARA BioSciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 04, 2010: DARA BioSciences Successfully Completes Phase I Clinical Study Of DB959 for Treatment Of Type 2 Diabetes
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer
Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with Novel Therapeutics" Meeting
Nov 19, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The Mechanisms And Treatment Of Neuropathic Pain" Meeting
Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes .
Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions
Mar 10, 2009: United States Food And Drug Administration Approves DARA Investigational New Drug Application (IND) For DB959.
Financial Deals Landscape
DARA BioSciences, Inc., Deals Volume Summary, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary By Region, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
DARA BioSciences, Inc. Detailed Deal Summary
Acquisition
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
Equity Offering
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
Licensing Agreements
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Massachusetts General Hospital
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 74
LIST OF TABLES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, 2010
DARA BioSciences, Inc. – Pipeline by Stage of Development, 2010
DARA BioSciences, Inc. – Monotherapy Products in Pipeline, 2010
DARA BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2010
DARA BioSciences, Inc. – Phase III, 2010
DARA BioSciences, Inc. - Phase II, 2010
DARA BioSciences, Inc. - Phase I, 2010
DARA BioSciences, Inc. - Pipeline By Therapeutic Class, 2010
DARA BioSciences, Inc. - Pipeline By Target, 2010
DARA BioSciences, Inc. – Pipeline By Molecule Type, 2010
DARA BioSciences, Inc. – Recent Pipeline Updates, 2010
DARA BioSciences, Inc. - Dormant Developmental Projects, 2010
DARA BioSciences, Inc., Subsidiaries
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary by Region, 2004 to YTD 2010
DARA BioSciences, Inc., Deals Summary, 2004 to YTD 2010
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Massachusetts General Hospital 73
LIST OF FIGURES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, 2010
DARA BioSciences, Inc. – Pipeline by Stage of Development, 2010
DARA BioSciences, Inc. – Monotherapy Products in Pipeline, 2010
DARA BioSciences, Inc. – Combination Treatment Modalities in Pipeline, 2010
DARA BioSciences, Inc. – Pipeline By Therapeutic Class, 2010
DARA BioSciences, Inc. - Pipeline By Target, 2010
DARA BioSciences, Inc. – Pipeline By Molecule Type, 2010 33